Functional Impairment and Painful Physical Symptoms in Patients with Major Depressive Disorder Treated with Antidepressants: Real-World Evidence from the Middle East

Table 2: Mean levels (raw values) of SDS total and subscores at baseline and at 24 weeks, by treatment cohorts.

Outcome	Duloxetine	SSRI	P-value	Effect size^a
At Baseline
SDS Total Score	17.36 (6.00)	15.66 (6.28)	0.012	0.28
SDS Work Score	5.35 (2.66)	5.11 (2.41)	0.186	0.09
SDS Social Life Score	6.24 (2.16)	5.35 (2.17)	<0.001	0.41
SDS Family Life Score	5.77 (2.29)	5.20 (2.19)	0.019	0.25
At 24 weeks
SDS Total Score	3.41 (3.06)	4.60 (3.21)	0.008	-0.38
SDS Work Score	1.09 (1.23)	1.67 (1.27)	0.001	-0.47
SDS Social Life Score	1.24 (1.04)	1.51 (1.11)	0.087	-0.25
SDS Family Life Score	1.08 (1.01)	1.41 (1.04)	0.024	-0.32

^a These show effect sizes of differences in functional impairment between treatment cohorts. Abbreviations: SDS, Sheehan Disability Scale; SSRI, Selective Serotonin Reuptake Inhibitor